“…Minimal efficacy at sufficiently low doses as well as short duration of action, however, limited its use for further development. Pinkerton et al (2005) reported an alternative series of mGlu2 PAMs, of which the prototypic example biphenyl-indanone A (BINA) demonstrates long-lasting activity in some animal models used to predict potential antipsychotic and anxiolytic activity (Galici et al, 2006). Recently, the structurally novel allosteric potentiator N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenxoy)methylbenzyl)-1-methyl-1H-imidazo-4-carboxamide (THIIC; also known as LY2607540), which seems to have activity in models predicting either anxiolytic or antidepressant effects, was reported (Fell et al, 2011).…”